AI-focused drug discovery remained a funding magnet, with Chai Discovery reporting a $400 million Series C that more than triples its valuation from a prior round and pushes total funding above $600 million. The company is using its AI-generated molecule modeling approach to support external collaborations, including reported usage by large pharma. In parallel coverage from biotech industry sessions, companies reiterated that AI adoption is expanding across target discovery and preclinical model development, while analysts pointed to persistent gaps in reproducibility and data transparency for in silico models. The combination of new megafunding and ongoing methodological scrutiny highlights a two-track picture: scale-up capital is moving quickly, but practical validation and reproducibility remain gating factors. For the sector, the Chai round signals that investors are still willing to underwrite early-stage AI molecule platforms—especially when they can point to integration with established drug-development pipelines and partner workflows.